The Reinecker laboratory unravels and targets molecular mechanisms of key human genetic variants that cause chronic inflammatory diseases and cancer by creating novel genetic mouse and human organotypic model systems.
My research interests include prevention of progression of renal diseases, diagnoses, and management of lipid disorders in renal disease, hypertensive nephrosclerosis, the role of angiotensin II converting enzyme inhibitors, and angiotensin II receptor blockers in renal disease.
The Saxena lab's research interests include Icodextin in high peritoneal transporters; Kremezin study in patients with chronic kidney disease; SV40 in focal segmental glomerulosclerosis; molecular studies in lupus nephritis.
Dr. Vongpatanasin studies neural control of blood pressure and the influence of various hormones and antihypertensive agents on autonomic control of blood pressure in humans.
We use in vivo models of ischemic acute kidney injury in mice, and in vitro model systems to perform detailed studies of proinflammatory genes activated by renal ischemia/reperfusion.
Our laboratory is focused on the molecular control of lipid metabolism, particularly in the intestinal tract. We employ a variety of disciplines including molecular and cell biology, mouse models and organoid technologies.
Chung Lab uses primary human specimens, patient-derived xenograft models, and genetically engineered mouse models to study the molecular mechanisms underlying disease stem cell function in hematologic malignancies.
The Turer Lab is interested in finding genes with novel functions in intestinal immune homeostasis. Our projects generally involve a mix of experimental approaches examining both the intestinal epithelium as well as hematopoietic causes of intestinal inflammation.
The research focus in the Corbin lab investigates strategies that exploits the deviant metabolism of cancer cells (namely the reprogramming of lipid metabolism and altered redox biology) for therapeutic purposes.
In prior work, my laboratory focused on identifying novel mechanisms of therapy-resistance and progression in breast, prostate and ovarian cancer.
